Twist Bioscience (NASDAQ:TWST) Given New $52.00 Price Target at Barclays

Twist Bioscience (NASDAQ:TWST) had its price objective cut by Barclays from $55.00 to $52.00 in a report released on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other research analysts also recently issued reports about the company. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Robert W. Baird upped their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday. Leerink Partners lifted their price objective on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Scotiabank upped their target price on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a report on Tuesday. Finally, Evercore ISI raised their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Trading Down 0.3 %

NASDAQ:TWST opened at $41.32 on Tuesday. Twist Bioscience has a twelve month low of $23.00 and a twelve month high of $60.90. The company has a market capitalization of $2.42 billion, a P/E ratio of -10.82 and a beta of 1.78. The firm has a 50-day moving average price of $43.99 and a two-hundred day moving average price of $46.18.

Insider Activity at Twist Bioscience

In related news, insider Dennis Cho sold 1,507 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the transaction, the insider now directly owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. This trade represents a 1.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert Chess sold 3,600 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $47.26, for a total value of $170,136.00. Following the sale, the director now directly owns 21,641 shares of the company’s stock, valued at approximately $1,022,753.66. This trade represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 98,118 shares of company stock worth $4,391,151. 3.92% of the stock is owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC increased its position in Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after purchasing an additional 26,145 shares in the last quarter. Barclays PLC grew its stake in Twist Bioscience by 214.8% during the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after buying an additional 104,420 shares during the period. XTX Topco Ltd increased its position in shares of Twist Bioscience by 36.7% in the third quarter. XTX Topco Ltd now owns 15,518 shares of the company’s stock worth $701,000 after acquiring an additional 4,169 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Twist Bioscience by 188.5% in the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares during the period. Finally, State Street Corp lifted its holdings in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after acquiring an additional 526,028 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.